Johan Hansson's Group
Our research group focuses on:
1. Epidemiological studies in which health and population registers are used to map factors linked to melanoma disease.
2. Preventive studies are ongoing to identify high-risk individuals, such as those with genetic predisposition and also to identify unknown genetic factors.
3. A phase II study has recently been initiated in which we investigate whether the effect of immunotherapy can be improved by adding precision radiation to the metastases (the PROMMEL study).
4. Studies are ongoing to find molecular factors that may predict treatment effect in patients with metastatic melanoma. We evaluate based on real world data and data from clinical studies, new biomarkers that can predict the effect of immunotherapy and targeted therapy (BioMelanoma).
5. Clinically relevant issues regarding genetic predisposition, treatment prediction and the emergence of treatment resistance in metastatic melanoma are also elucidated through studies on tumor models in in vitro and in vivo studies.
Johan Hansson, professor emeritus
Karin Kjulin, research coordinator
Suzanne Egyházi Brage, PhD, researcher, deputy group leader
Veronica Höiom, PhD, researcher
Hildur Helgadottir, MD, PhD, team leader
Johan Falkenius, MD, PhD
Muyi Yang, PhD
Ishani Das, PhD, affiliated
Fernanda Costa Svedman, MD, PhD
Ellen Backlund, MD, PhD student